<DOC>
	<DOCNO>NCT02639676</DOCNO>
	<brief_summary>Pregnant mother develop high blood pressure vascular problem ( preeclampsia ) deliver baby increase neonatal health problem , include lung disease vascular complication , later life . Investigators evaluate whether infant mother preeclampsia evidence impair development lung blood vessel .</brief_summary>
	<brief_title>Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung Vascular Development</brief_title>
	<detailed_description>The overall objective study determine whether anti-angiogenic environment preeclampsia result pulmonary vascular dysfunction infant . Specifically , study investigator hypothesize anti- angiogenic environment preeclampsia impair pulmonary development promote vascular dysfunction infant . Furthermore , study investigator hypothesize circulate progenitor cell ( CPC ) measurement cord blood correlate infant pulmonary ( Aim # 1 ) systemic vascular ( Aim # 2 ) function . Study investigator determine whether pro-angiogenic circulate progenitor cell ( CPC ) versus non-circulating progenitor cell ratio cord blood pregnancy complicate preeclampsia predicts pulmonary diffuse capacity systemic vascular dysfunction , well respiratory distress syndrome ( RDS ) bronchopulmonary dysplasia ( BPD ) . This research represent important translational study extends observation make pre-clinical animal model clearly establish critical relationship angiogenesis lung development . Preliminary data strongly suggest relationship pro-angiogenic circulating progenitor cell ( CPCs ) , bronchopulmonary dysplasia ( BPD ) , pulmonary diffusion human infant . Investigators evaluate whether circulate progenitor cell ( CPC ) biomarker develop bronchopulmonary dysplasia ( BPD ) , investigator relate circulate progenitor cell ( CPCs ) underlie pathophysiology , assess pulmonary function test method develop difficult age group evaluate . A positive finding study would provide rationale future translational study evaluate therapeutic potential circulating progenitor cell ( CPCs ) stimulate lung development premature infant , currently know therapeutic intervention minimize prevent development bronchopulmonary dysplasia ( BPD ) . One several approach could apply future increase circulate progenitor cell ( CPCs ) premature infant : 1 ) pharmacologic mobilization pro-angiogenic cell bone marrow , 2 ) expansion pro-angiogenic cell infant 's cord blood autologous infusion , 3 ) transfusion pool pro-angiogenic cell multiple donor .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<criteria>Group 1 : Infants bear mother preeclampsia Clinical diagnosis preeclampsia per ACOG Task Force Hypertension Pregnancy 2013 report Anticipated delivery 26+0 week gestation great . Infant viable Cardiopulmonary defect Chest wall abnormality Genetic anomaly Maternal history Diabetes Mellitus Multiple gestation Group 2 : Infants bear mother normotensive pregnancy Inclusion Criteria Normotensive pregnancy Anticipated delivery 26+0 week gestation great . Exclusion Criteria Maternal history gestational diabetes Multiple gestation Genetic anomaly Chest wall abnormality Chronic Gestational hypertension Cardiopulmonary defect Infant viable</criteria>
	<gender>All</gender>
	<minimum_age>26 Weeks</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Infant</keyword>
	<keyword>Bronchopulmonary Dysplasia</keyword>
	<keyword>Premature</keyword>
</DOC>